D1EX34 Stock Overview
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
DexCom, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.79 |
| 52 Week High | US$14.45 |
| 52 Week Low | US$7.60 |
| Beta | 1.21 |
| 1 Month Change | -3.54% |
| 3 Month Change | 6.05% |
| 1 Year Change | 3.15% |
| 3 Year Change | 20.97% |
| 5 Year Change | n/a |
| Change since IPO | 15.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| D1EX34 | BR Medical Equipment | BR Market | |
|---|---|---|---|
| 7D | -4.9% | 2.4% | 0.9% |
| 1Y | 3.1% | -2.5% | 15.0% |
Return vs Industry: D1EX34 exceeded the BR Medical Equipment industry which returned -2.5% over the past year.
Return vs Market: D1EX34 underperformed the BR Market which returned 15% over the past year.
Price Volatility
| D1EX34 volatility | |
|---|---|
| D1EX34 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.7% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in BR Market | 8.8% |
| 10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: D1EX34 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine D1EX34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 9,550 | Kevin Sayer | www.dexcom.com |
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
DexCom, Inc. Fundamentals Summary
| D1EX34 fundamental statistics | |
|---|---|
| Market cap | R$252.99b |
| Earnings (TTM) | R$3.27b |
| Revenue (TTM) | R$19.45b |
77.3x
P/E Ratio13.0x
P/S RatioIs D1EX34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| D1EX34 income statement (TTM) | |
|---|---|
| Revenue | US$3.80b |
| Cost of Revenue | US$1.41b |
| Gross Profit | US$2.39b |
| Other Expenses | US$1.75b |
| Earnings | US$639.30m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.61 |
| Gross Margin | 62.82% |
| Net Profit Margin | 16.82% |
| Debt/Equity Ratio | 108.4% |
How did D1EX34 perform over the long term?
See historical performance and comparison